dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Bairaktari, Eleni Th | en |
dc.contributor.author | Kalef-Ezra, J. A. | en |
dc.contributor.author | Athanasiades, A. | en |
dc.contributor.author | Seferiadis, C. | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Bairaktari, Eleni Th | en |
dc.creator | Kalef-Ezra, J. A. | en |
dc.creator | Athanasiades, A. | en |
dc.creator | Seferiadis, C. | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:54:21Z | |
dc.date.available | 2018-06-22T09:54:21Z | |
dc.date.issued | 1996 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42319 | |
dc.description.abstract | The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals served as controls. Seventy-five percent of the patients had increased mean serum levels of sIL-2R (1539 ± 155 U/ml), while normal controls had mean levels of 555 ± 31 U/ml (p < 0.001). The relationship with hepatic or lymph nodal metastases showed no statistically significant difference (p = 0.34 and p = 0.47, respectively). Serum sIL-2R levels showed a linear correlation with CEA (p < 0.05). Patients with lower pretreatment sIL-2R levels (less than 1.200 U/ml) had a longer survival than patients with higher initial levels (more than 1.200 U/ml) (p = 0.0049). In conclusion, the present work shows that the serum levels of sIL-2R: a) are elevated in patients with advanced colorectal cancer, b) have no relationship with the type of metastases, c) correlate with serum CEA and d) have a prognostic value for survival. | en |
dc.language.iso | eng | en |
dc.source | International Journal of Biological Markers | en |
dc.subject | Age factors | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Controlled study | en |
dc.subject | Female | en |
dc.subject | Major clinical study | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer survival | en |
dc.subject | Predictive value of tests | en |
dc.subject | Prognosis | en |
dc.subject | Survival analysis | en |
dc.subject | Time factors | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Male | en |
dc.subject | Interleukin-2 | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Receptors | en |
dc.subject | Colorectal cancer | en |
dc.subject | Colorectal carcinoma | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Survival time | en |
dc.subject | Interleukin 2 receptor | en |
dc.subject | Liver metastasis | en |
dc.subject | Biological | en |
dc.subject | Tumor markers | en |
dc.subject | Tumor marker | en |
dc.subject | Carcinoembryonic antigen | en |
dc.subject | Tumor markers | en |
dc.subject | Sex factors | en |
dc.subject | Blood level | en |
dc.subject | Reference values | en |
dc.subject | Ca 19-9 antigen | en |
dc.subject | Soluble interleukin-2 receptors | en |
dc.subject | Ca 19-9 | en |
dc.subject | Ca-19-9 antigen | en |
dc.subject | Cea | en |
dc.title | Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 11 | |
dc.description.issue | 1 | |
dc.description.startingpage | 6 | |
dc.description.endingpage | 11 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |